X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/29/2854733/0/en/Adagene-Reports-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2024/03/07/2842715/0/en/Adagene-Appoints-Heinz-Josef-Lenz-M-D-FACP-to-Scientific-and-Strategic-Advisory-Board.html
https://www.globenewswire.com//news-release/2024/02/27/2835951/0/en/Adagene-to-Present-at-the-Leerink-Partners-Global-Biopharma-Conference-2024.html
https://www.globenewswire.com//news-release/2024/02/09/2826677/0/en/Adagene-Announces-Progress-and-Expansion-of-Clinical-Collaboration-Program-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-KEYTRUDA-pembrolizumab-to-Demonstra.html
https://www.globenewswire.com//news-release/2024/01/16/2810362/0/en/Adagene-Presents-Interim-Results-Reinforcing-Best-in-Class-Profile-of-Masked-anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-Pembrolizumab-in-Metastatic-Microsatellite-s.html
https://www.globenewswire.com//news-release/2024/01/04/2803770/0/en/Adagene-To-Present-Interim-Results-of-Masked-anti-CTLA-4-SAFEbody-ADG126-muzastotug-in-Combination-with-Pembrolizumab-in-MSS-CRC-at-ASCO-GI-Symposium.html
https://www.globenewswire.com//news-release/2023/11/03/2773331/0/en/Adagene-Presents-Data-Demonstrating-the-Best-in-Class-Therapeutic-Index-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-at-SITC-2023.html
https://www.globenewswire.com//news-release/2023/10/12/2759194/0/en/Adagene-Announces-Poster-Presentation-on-Optimal-Dose-Selection-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-at-Upcoming-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting.html
https://www.globenewswire.com//news-release/2023/09/07/2739093/0/en/Adagene-to-Present-at-Investor-and-Scientific-Conferences-in-September.html
https://www.fiercebiotech.com/biotech/adc-therapeutics-calls-it-quits-2019-adagene-research-and-licensing-pact
Market Place
Share 
